knowledge -WSS

knowledge

author：comprehensive 2025-09-29 20:00:17 - browse：8629

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Q&A: Jennifer Adair on making gene therapy available globally

Wikipedia

WSS

H5N1 bird flu virus started spreading in cows in Texas in December

Cholera vaccine supply gets boost as demand surges globally

MultiPlan and major insurers sued for alleged medical price

H5N1 bird flu found in pasteurized milk: what we know

Exact Sciences stock tumbles despite strong cancer detection sales

Q&A: Jennifer Adair on making gene therapy available globally

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Apple is now the first public company to be valued at $3 trillion

Cholera vaccine supply gets boost as demand surges globally

Anesthesiologist group: stop taking Ozempic before surgery

6 phony surgeries that take placebo to the extreme

Medical leaders decry Supreme Court decision on affirmative action

In utero gene editing: an explainer

Duchenne breakthrough therapy leaves behind pioneering families

In utero gene editing: an explainer

Moonlake's readout produced a cash windfall. Risks remain

Cancer researcher Catriona Jamieson is sending tumors into space

knowledge

A new nitrogen execution bill also undermines medical licensing

New documents shed light on MD Anderson Cancer Institute feud

A new nitrogen execution bill also undermines medical licensing

PBM reform efforts get punted in Congress

Getting Alzheimer's drug Leqembi to patients can be a challenge

Close Medicare's dangerous gaps in addiction treatment coverage

Wikipedia

Wikipedia

focus

Wikipedia